Future studies may investigate the relationships among the administration of the BACE-1 inhibitor and in-vivo measures of AD-like neuropathology (e.g., amyloid β, tau, neuroinflammation), the present EEG markers, and cognitive functions. Here, MAPT is linked to Alzheimer disease.